


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:51:53Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12405363" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12405363</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Cardiovasc Imaging</journal-id><journal-id journal-id-type="iso-abbrev">Int J Cardiovasc Imaging</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>The International Journal of Cardiovascular Imaging</journal-title></journal-title-group><issn pub-type="ppub">1569-5794</issn><issn pub-type="epub">1875-8312</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12405363</article-id><article-id pub-id-type="pmcid-ver">PMC12405363.1</article-id><article-id pub-id-type="pmcaid">12405363</article-id><article-id pub-id-type="pmcaiid">12405363</article-id><article-id pub-id-type="pmid">40824411</article-id><article-id pub-id-type="doi">10.1007/s10554-025-03472-0</article-id><article-id pub-id-type="publisher-id">3472</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Impact of alirocumab on neoatherosclerosis formation and vessel healing after drug-eluting stent implantation in patients with acute myocardial infarction: a substudy of the PACMAN-AMI trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Kakizaki</surname><given-names initials="R">Ryota</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ueki</surname><given-names initials="Y">Yasushi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Koskinas</surname><given-names initials="KC">Konstantinos C.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shibutani</surname><given-names initials="H">Hiroki</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Losdat</surname><given-names initials="S">Sylvain</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Biccir&#232;</surname><given-names initials="FG">Flavio G.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Otsuka</surname><given-names initials="T">Tatsuhiko</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>H&#228;ner</surname><given-names initials="JD">Jonas D.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>L&#248;nborg</surname><given-names initials="J">Jacob</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kaiser</surname><given-names initials="C">Christoph</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Iglesias</surname><given-names initials="JF">Juan F.</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ondracek</surname><given-names initials="AS">Anna S.</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Spirk</surname><given-names initials="D">David</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Siontis</surname><given-names initials="GCM">George C. M.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Daemen</surname><given-names initials="J">Joost</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Engstr&#248;m</surname><given-names initials="T">Thomas</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lang</surname><given-names initials="IM">Irene M.</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>R&#228;ber</surname><given-names initials="L">Lorenz</given-names></name><address><email>lorenz.raeber@insel.ch</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff12">12</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01q9sj412</institution-id><institution-id institution-id-type="GRID">grid.411656.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 0479 0855</institution-id><institution>Department of Cardiology, </institution><institution>Bern University Hospital, Inselspital, University of Bern, </institution></institution-wrap>Bern, Switzerland </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0244rem06</institution-id><institution-id institution-id-type="GRID">grid.263518.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 1507 4692</institution-id><institution>Department of Cardiovascular Medicine, </institution><institution>Shinshu University School of Medicine, </institution></institution-wrap>Nagano, Japan </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/001xjdh50</institution-id><institution-id institution-id-type="GRID">grid.410783.9</institution-id><institution-id institution-id-type="ISNI">0000 0001 2172 5041</institution-id><institution>Division of Cardiology, Department of Medicine II, </institution><institution>Kansai Medical University, </institution></institution-wrap>Osaka, Japan </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02k7v4d05</institution-id><institution-id institution-id-type="GRID">grid.5734.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 0726 5157</institution-id><institution>Department of Clinical Research, </institution><institution>University of Bern, </institution></institution-wrap>Bern, Bern, Switzerland </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03e0v3w65</institution-id><institution>Department of Cardiology, </institution><institution>Itabashi Chuo Medical Center, </institution></institution-wrap>Tokyo, Japan </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03mchdq19</institution-id><institution-id institution-id-type="GRID">grid.475435.4</institution-id><institution>Department of Cardiology, </institution><institution>Rigshospitalet, Copenhagen University Hospital, </institution></institution-wrap>Copenhagen, Denmark </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04k51q396</institution-id><institution-id institution-id-type="GRID">grid.410567.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 1882 505X</institution-id><institution>Department of Cardiology, </institution><institution>University Hospital Basel, </institution></institution-wrap>Basel, Switzerland </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01m1pv723</institution-id><institution-id institution-id-type="GRID">grid.150338.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0721 9812</institution-id><institution>Department of Cardiology, </institution><institution>Geneva University Hospitals, </institution></institution-wrap>Geneva, Switzerland </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05n3x4p02</institution-id><institution-id institution-id-type="GRID">grid.22937.3d</institution-id><institution-id institution-id-type="ISNI">0000 0000 9259 8492</institution-id><institution>Department of Cardiology, </institution><institution>Medical University of Vienna, </institution></institution-wrap>Vienna, Austria </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02k7v4d05</institution-id><institution-id institution-id-type="GRID">grid.5734.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 0726 5157</institution-id><institution>Institute of Pharmacology, Bern University Hospital, </institution><institution>University of Bern, </institution></institution-wrap>Bern, Switzerland </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/018906e22</institution-id><institution-id institution-id-type="GRID">grid.5645.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0459 992X</institution-id><institution>Department of Cardiology, </institution><institution>Erasmus University Medical Center, </institution></institution-wrap>Rotterdam, The Netherlands </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02k7v4d05</institution-id><institution-id institution-id-type="GRID">grid.5734.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 0726 5157</institution-id><institution>Department of Cardiology, </institution><institution>Bern University Hospital, Inselspital, University of Bern, </institution></institution-wrap>Freiburgstrasse 18, Bern, 3010 Switzerland </aff></contrib-group><pub-date pub-type="epub"><day>18</day><month>8</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>41</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496088</issue-id><fpage>1739</fpage><lpage>1748</lpage><history><date date-type="received"><day>5</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>21</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>18</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="10554_2025_Article_3472.pdf"/><abstract id="Abs1"><p id="Par1">Higher on-treatment levels of low-density lipoprotein cholesterol in statin-treated patients were reportedly associated with the occurrence of neoatherosclerosis after drug-eluting stent (DES) implantation. We aimed to investigate the impact of alirocumab added to high-intensity statin therapy on neoatherosclerosis formation among patients with acute myocardial infarction (AMI) treated with DES. This was a pre-specified substudy of the PACMAN-AMI trial, a randomized, double-blind trial comparing alirocumab versus placebo added to high-intensity statin therapy in AMI patients. The present study included patients undergoing optical coherence tomography assessment of DES in the culprit lesion at one year. The frequency of neoatherosclerosis, neointimal thickness, and strut malapposition were compared between treatment groups. Among 191 patients (95 with alirocumab and 96 with placebo), neoatherosclerosis was observed in 13 patients (6.8%) at one year. There was no significant difference in the frequency of neoatherosclerosis between treatment groups (alirocumab 4.2% vs. placebo 9.4%, <italic toggle="yes">P</italic>&#8201;=&#8201;0.25). Among 11 patients with lipid-laden neointima, minimal fibrous cap thickness was greater in the alirocumab group than in the placebo group (217.5&#8201;&#177;&#8201;122.5 vs. 87.8&#8201;&#177;&#8201;49.1&#160;&#956;m, <italic toggle="yes">P</italic>&#8201;=&#8201;0.02). Neointimal thickness (136.2&#8201;&#177;&#8201;71.1 vs. 151.4&#8201;&#177;&#8201;101.4&#160;&#956;m, <italic toggle="yes">P</italic>&#8201;=&#8201;0.45) and the frequency of malapposed struts (0.94 vs. 0.53%, <italic toggle="yes">P</italic>&#8201;=&#8201;0.27) were comparable between treatment groups. Among AMI patients treated with DES, there was no significant impact of alirocumab on the frequency of neoatherosclerosis and vessel healing at one year. The observed numerical difference and the finding of more stable neoatheroma in the alirocumab group need further investigation in larger studies with extended follow-up.</p><sec><title>Graphical abstract</title><p id="Par2">Alirocumab was associated with a numerically favourable, though not statistically significant, reduction in neoatherosclerosis at 1 year in AMI culprit lesions treated with newer-generation DES.</p><p id="Par3">
<graphic position="anchor" id="MO1" orientation="portrait" xlink:href="10554_2025_3472_Figa_HTML.jpg"/>
</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s10554-025-03472-0.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Proprotein convertase subtilisin/Kexin type 9 inhibitor</kwd><kwd>Low-density lipoprotein cholesterol</kwd><kwd>Neoatherosclerosis</kwd><kwd>Neointimal hyperplasia</kwd></kwd-group><funding-group><award-group><funding-source><institution>University of Bern</institution></funding-source></award-group><open-access><p>Open access funding provided by University of Bern</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature B.V. 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par4">Drug-eluting stents (DES) have improved the overall safety and efficacy of percutaneous coronary intervention (PCI) [<xref ref-type="bibr" rid="CR1">1</xref>]. However, late stent failures including in-stent restenosis and stent thrombosis continue to occur at relatively low, but constant rates [<xref ref-type="bibr" rid="CR2">2</xref>&#8211;<xref ref-type="bibr" rid="CR4">4</xref>]. Neoatherosclerosis, histologically characterized by the accumulation of lipid-laden macrophage foam cells, necrotic core, and calcification in the neointimal tissue of the stented segment [<xref ref-type="bibr" rid="CR5">5</xref>], is increasingly recognized as a major pathophysiological mechanism underlying late stent failures [<xref ref-type="bibr" rid="CR6">6</xref>&#8211;<xref ref-type="bibr" rid="CR8">8</xref>]. In culprit lesions of acute myocardial infarction (AMI), delayed vessel healing, characterized by less neointimal thickness, higher prevalence of uncovered struts, and greater inflammation, leads to more severe endothelial dysfunction and impaired endothelial barrier, potentially resulting in an accelerated formation of neoatherosclerosis [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par5">Although procedure-related factors including stent type (i.e. strut thickness, polymer type), strut apposition, and underlying plaque type are important substrates for neoatherosclerosis formation and vessel healing following DES implantation, previous studies have demonstrated a significant positive association between serum low-density lipoprotein cholesterol (LDL-C) levels and the occurrence of neoatherosclerosis [<xref ref-type="bibr" rid="CR10">10</xref>&#8211;<xref ref-type="bibr" rid="CR12">12</xref>]. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) added to statins potently reduce LDL-C and thereby result in significant plaque regression and cardiovascular benefits compared with statin therapy alone [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. To date, the effect of intensive lipid-lowering therapy with PCSK9i on top of high-intensity statin on neoatherosclerosis formation and late stent healing remains to be elucidated.</p><p id="Par6">Therefore, we have performed a predefined substudy of the randomized, double-blind PACMAN-AMI (effects of the PCSK9 antibody AliroCuMab on coronary Atherosclerosis in patieNtswith Acute Myocardial Infarction) trial to assess whether intensive lipid-lowering therapy with alirocumab impacts on the frequency of neoatherosclerosis and vessel healing.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study population</title><p id="Par7">The PACMAN-AMI trial (<ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT03067844">NCT03067844</ext-link>) was an investigator-initiated, multicenter, randomized, double-blind clinical trial conducted at 9 centers in 4 European countries (Switzerland, Austria, Denmark, and the Netherlands). The study design and main results of the PACMAN-AMI trial has been reported previously [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. In brief, the PACMAN-AMI trial included 300 patients with 18 years or older who underwent PCI of the culprit lesion for treatment of ST-elevation or non-ST-elevation myocardial infarction. Patients were randomized to receive biweekly alirocumab or placebo for 52 weeks in addition to high-intensity statin therapy (rosuvastatin 20&#160;mg). The present pre-specified substudy included patients who underwent optical coherence tomography (OCT) imaging for the culprit lesion of AMI at 52 weeks following primary PCI. OCT recording was performed if the operator deemed it feasible for the culprit lesion at one year follow-up. PCI was performed in accordance with the European Society of Cardiology Guidelines [<xref ref-type="bibr" rid="CR16">16</xref>] and DES selection was at the discretion of the operator. All patients provided written informed consent, and the study was approved by the ethical committee at each site.</p></sec><sec id="Sec4"><title>Acquisition and analysis of intracoronary imaging</title><p id="Par8">The OCT imaging was performed using a frequency-domain OCT system (Dragon Fly, LightLab, St. Jude Medical, St. Paul, MN, USA). OCT images were analyzed at independent core laboratory (Bern University Hospital, Bern, Switzerland) by experienced analysts. Cross-sectional OCT images were evaluated quantitatively and qualitatively with an interval of 0.4&#160;mm within the stented segments using proprietary software (QCU-CMS version 4.69 software, LKEB, Leiden, The Netherlands). Neointima was defined as the tissue between the luminal border and the endoluminal border of the struts. Neoatherosclerosis was defined as either the presence of lipid-laden neointima or calcification with a longitudinal extension of &#8805;&#8201;1.2&#160;mm, the presence of macrophage, or the presence of cholesterol crystals [<xref ref-type="bibr" rid="CR17">17</xref>]. Fibroatheroma were characterized as a signal-poor region displaying high attenuation (to differentiate from layered neointima) with diffuse borders and a lateral extension of at least one quadrant [<xref ref-type="bibr" rid="CR18">18</xref>]. Calcification were defined as signal-poor regions with low attenuation and clear borderlines. Macrophage was defined as lines or dots with strong signal attenuation producing a shadow with a sharply delineated lateral border. In-stent cholesterol crystal was defined as thin and linear structures with high backscattering without attenuation within the neointima. Stent strut coverage and malapposition were defined and measured as described previously [<xref ref-type="bibr" rid="CR18">18</xref>].</p></sec><sec id="Sec5"><title>Study endpoints</title><p id="Par9">Primary endpoint was the frequency of neoatherosclerosis at 1 year, and key secondary endpoints were neointimal area, neointimal thickness, and percentage of uncovered and malapposed struts at 1 year.</p></sec><sec id="Sec6"><title>Statistical analysis</title><p id="Par10">Continuous variables were summarized as mean (standard deviation) or median [interquartile range]. Between-group comparisons were conducted using Student t-tests or Wilcoxon-Mann-Whitney tests, as appropriate. Categorical variables were summarized as counts (percentage) and compared between groups using Fisher&#8217;s exact tests. Statistical significance was set to 0.05. All statistical analyses were performed using Stata 17 (StataCorp LLC, College Station, TX) and R 4.4.1 (R Core Team).</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>Baseline and procedural characteristics</title><p id="Par11">A total of 191 patients (95 in the alirocumab group and 96 in the placebo group) undergoing OCT imaging for the culprit stents at 1 year were analyzed for the current sub-study (Supplementary Fig.&#160;1). Baseline clinical and procedural characteristics were well-balanced between treatment groups (Tables&#160;<xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref>). LDL-C level at follow-up was 23.2&#8201;&#177;&#8201;23.2&#160;mg/dL in the alirocumab group and 73.5&#8201;&#177;&#8201;30.9&#160;mg/dL in the placebo group. Among 265 patients who received serial angiography, quantitative coronary angiography results were comparable between the alirocumab group and the placebo group (Supplementary Table 1). There were no significant differences in baseline characteristics between patients with and without OCT for the culprit lesion at 1 year follow-up, except for the frequency of dyslipidemia and P2Y12 inhibitor at baseline (Supplementary Table 2). Quantitative coronary angiography results were also comparable between patients with and without OCT at 1 year follow-up.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Patient characteristics and medication</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Overall<break/><italic toggle="yes">n</italic>&#8201;=&#8201;191</th><th align="left" colspan="1" rowspan="1">Alirocumab<break/><italic toggle="yes">n</italic>&#8201;=&#8201;95</th><th align="left" colspan="1" rowspan="1">Placebo<break/><italic toggle="yes">n</italic>&#8201;=&#8201;96</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age, years</td><td align="left" colspan="1" rowspan="1">58.1 (9.5)</td><td align="left" colspan="1" rowspan="1">57.9 (10.1)</td><td align="left" colspan="1" rowspan="1">58.4 (8.9)</td><td char="." align="char" colspan="1" rowspan="1">0.69</td></tr><tr><td align="left" colspan="1" rowspan="1">Men, n (%)</td><td align="left" colspan="1" rowspan="1">160 (83.8)</td><td align="left" colspan="1" rowspan="1">83 (87.4)</td><td align="left" colspan="1" rowspan="1">77 (80.2)</td><td char="." align="char" colspan="1" rowspan="1">0.24</td></tr><tr><td align="left" colspan="1" rowspan="1">BMI, kg/m2</td><td align="left" colspan="1" rowspan="1">27.9 (4.3)</td><td align="left" colspan="1" rowspan="1">27.3 (3.9)</td><td align="left" colspan="1" rowspan="1">28.4 (4.6</td><td char="." align="char" colspan="1" rowspan="1">0.06</td></tr><tr><td align="left" colspan="1" rowspan="1">Medical history, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Arterial hypertension</td><td align="left" colspan="1" rowspan="1">81 (42.4)</td><td align="left" colspan="1" rowspan="1">34 (35.8)</td><td align="left" colspan="1" rowspan="1">47 (49.0)</td><td char="." align="char" colspan="1" rowspan="1">0.08</td></tr><tr><td align="left" colspan="1" rowspan="1">Dyslipidemia</td><td align="left" colspan="1" rowspan="1">162 (84.8)</td><td align="left" colspan="1" rowspan="1">79 (83.2)</td><td align="left" colspan="1" rowspan="1">83 (86.5)</td><td char="." align="char" colspan="1" rowspan="1">0.55</td></tr><tr><td align="left" colspan="1" rowspan="1">Diabetes</td><td align="left" colspan="1" rowspan="1">16 (8.4)</td><td align="left" colspan="1" rowspan="1">5 (5.3)</td><td align="left" colspan="1" rowspan="1">11 (11.5)</td><td char="." align="char" colspan="1" rowspan="1">0.19</td></tr><tr><td align="left" colspan="1" rowspan="1">Current smoking</td><td align="left" colspan="1" rowspan="1">87 (45.5)</td><td align="left" colspan="1" rowspan="1">49 (51.6)</td><td align="left" colspan="1" rowspan="1">38 (39.6)</td><td char="." align="char" colspan="1" rowspan="1">0.11</td></tr><tr><td align="left" colspan="1" rowspan="1">Previous myocardial infarction</td><td align="left" colspan="1" rowspan="1">2 (1.0)</td><td align="left" colspan="1" rowspan="1">1 (1.1)</td><td align="left" colspan="1" rowspan="1">1 (1.0)</td><td char="." align="char" colspan="1" rowspan="1">1.00</td></tr><tr><td align="left" colspan="1" rowspan="1">Previous PCI</td><td align="left" colspan="1" rowspan="1">3 (1.6)</td><td align="left" colspan="1" rowspan="1">1 (1.1)</td><td align="left" colspan="1" rowspan="1">2 (2.1)</td><td char="." align="char" colspan="1" rowspan="1">1.00</td></tr><tr><td align="left" colspan="1" rowspan="1">Peripheral arterial disease</td><td align="left" colspan="1" rowspan="1">3 (1.6)</td><td align="left" colspan="1" rowspan="1">1 (1.1)</td><td align="left" colspan="1" rowspan="1">2 (2.1)</td><td char="." align="char" colspan="1" rowspan="1">1.00</td></tr><tr><td align="left" colspan="1" rowspan="1">Family history of CAD</td><td align="left" colspan="1" rowspan="1">59 (30.9)</td><td align="left" colspan="1" rowspan="1">28 (29.5)</td><td align="left" colspan="1" rowspan="1">31 (32.3)</td><td char="." align="char" colspan="1" rowspan="1">0.75</td></tr><tr><td align="left" colspan="1" rowspan="1">Type of acute myocardial infarction, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">0.47</td></tr><tr><td align="left" colspan="1" rowspan="1">NSTEMI</td><td align="left" colspan="1" rowspan="1">85 (44.5)</td><td align="left" colspan="1" rowspan="1">45 (47.4)</td><td align="left" colspan="1" rowspan="1">40 (41.7)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">STEMI</td><td align="left" colspan="1" rowspan="1">106 (55.5)</td><td align="left" colspan="1" rowspan="1">50 (52.6)</td><td align="left" colspan="1" rowspan="1">56 (58.3)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Peak CK, IU/L</td><td align="left" colspan="1" rowspan="1">687 (1061)</td><td align="left" colspan="1" rowspan="1">770 (1191)</td><td align="left" colspan="1" rowspan="1">605 (915)</td><td char="." align="char" colspan="1" rowspan="1">0.29</td></tr><tr><td align="left" colspan="1" rowspan="1">Peak hs-cTnT, ng/mL</td><td align="left" colspan="1" rowspan="1">1189 (2734)</td><td align="left" colspan="1" rowspan="1">1417 (3311)</td><td align="left" colspan="1" rowspan="1">961 (1991)</td><td char="." align="char" colspan="1" rowspan="1">0.25</td></tr><tr><td align="left" colspan="1" rowspan="1">LVEF, %</td><td align="left" colspan="1" rowspan="1">53 (11)</td><td align="left" colspan="1" rowspan="1">53 (11)</td><td align="left" colspan="1" rowspan="1">53 (11)</td><td char="." align="char" colspan="1" rowspan="1">0.92</td></tr><tr><td align="left" colspan="1" rowspan="1">Medication, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Statin</td><td align="left" colspan="1" rowspan="1">26 (13.6)</td><td align="left" colspan="1" rowspan="1">11 (11.6)</td><td align="left" colspan="1" rowspan="1">15 (15.6)</td><td char="." align="char" colspan="1" rowspan="1">0.53</td></tr><tr><td align="left" colspan="1" rowspan="1">High-intensity statin therapy</td><td align="left" colspan="1" rowspan="1">13 (6.8)</td><td align="left" colspan="1" rowspan="1">6 (6.3)</td><td align="left" colspan="1" rowspan="1">7 (7.3)</td><td char="." align="char" colspan="1" rowspan="1">1.00</td></tr><tr><td align="left" colspan="1" rowspan="1">Ezetimibe</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Antiplatelet therapy</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Aspirin</td><td align="left" colspan="1" rowspan="1">13 (6.8)</td><td align="left" colspan="1" rowspan="1">7 (7.4)</td><td align="left" colspan="1" rowspan="1">6 (6.2)</td><td char="." align="char" colspan="1" rowspan="1">0.78</td></tr><tr><td align="left" colspan="1" rowspan="1">P2Y12 inhibitor</td><td align="left" colspan="1" rowspan="1">3 (1.6)</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1">3 (3.1)</td><td char="." align="char" colspan="1" rowspan="1">0.25</td></tr><tr><td align="left" colspan="1" rowspan="1">Anti-coagulant</td><td align="left" colspan="1" rowspan="1">2 (1.0)</td><td align="left" colspan="1" rowspan="1">1 (1.1)</td><td align="left" colspan="1" rowspan="1">1 (1.0)</td><td char="." align="char" colspan="1" rowspan="1">1.00</td></tr><tr><td align="left" colspan="1" rowspan="1">&#946;-Blocker</td><td align="left" colspan="1" rowspan="1">15 (7.9)</td><td align="left" colspan="1" rowspan="1">5 (5.3)</td><td align="left" colspan="1" rowspan="1">10 (10.4)</td><td char="." align="char" colspan="1" rowspan="1">0.28</td></tr><tr><td align="left" colspan="1" rowspan="1">ACEI</td><td align="left" colspan="1" rowspan="1">13 (6.8)</td><td align="left" colspan="1" rowspan="1">5 (5.3)</td><td align="left" colspan="1" rowspan="1">8 (8.3)</td><td char="." align="char" colspan="1" rowspan="1">0.57</td></tr><tr><td align="left" colspan="1" rowspan="1">ARB</td><td align="left" colspan="1" rowspan="1">20 (10.5)</td><td align="left" colspan="1" rowspan="1">7 (7.4)</td><td align="left" colspan="1" rowspan="1">13 (13.5)</td><td char="." align="char" colspan="1" rowspan="1">0.24</td></tr></tbody></table><table-wrap-foot><p>Values are count (percentage) or mean (SD). Abbreviations: ACEI: angiotensin converting enzyme inhibitor, ARB: angiotensin receptor blocker, BMI: body mass index, CAD: coronary artery disease, CK: creatinine kinase, cTnT: cardiac troponin T, LVEF: left ventricular ejection fraction, NSTEMI: non-ST-segment elevation myocardial infarction, PCI: percutaneous coronary intervention, STEMI: ST-segment elevation myocardial infarction</p></table-wrap-foot></table-wrap><table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Lesion and procedure characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Overall<break/><italic toggle="yes">n</italic>&#8201;=&#8201;191</th><th align="left" colspan="1" rowspan="1">Alirocumab<break/><italic toggle="yes">n</italic>&#8201;=&#8201;95</th><th align="left" colspan="1" rowspan="1">Placebo<break/><italic toggle="yes">n</italic>&#8201;=&#8201;96</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Target vessel location, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">0.20</td></tr><tr><td align="left" colspan="1" rowspan="1">Left anterior descending</td><td char="." align="char" colspan="1" rowspan="1">93 (48.7)</td><td char="." align="char" colspan="1" rowspan="1">47 (49.5)</td><td char="." align="char" colspan="1" rowspan="1">46 (47.9)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Left circumflex</td><td char="." align="char" colspan="1" rowspan="1">42 (22.0)</td><td char="." align="char" colspan="1" rowspan="1">25 (26.3)</td><td char="." align="char" colspan="1" rowspan="1">17 (17.7)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Right coronary artery</td><td char="." align="char" colspan="1" rowspan="1">56 (29.3)</td><td char="." align="char" colspan="1" rowspan="1">23 (24.2)</td><td char="." align="char" colspan="1" rowspan="1">33 (34.4)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Final TIMI flow, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">0.50</td></tr><tr><td align="left" colspan="1" rowspan="1">0</td><td char="." align="char" colspan="1" rowspan="1">0 (0.0)</td><td char="." align="char" colspan="1" rowspan="1">0 (0.0)</td><td char="." align="char" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">1</td><td char="." align="char" colspan="1" rowspan="1">0 (0.0)</td><td char="." align="char" colspan="1" rowspan="1">0 (0.0)</td><td char="." align="char" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">2</td><td char="." align="char" colspan="1" rowspan="1">1 (0.5)</td><td char="." align="char" colspan="1" rowspan="1">1 (1.1)</td><td char="." align="char" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">3</td><td char="." align="char" colspan="1" rowspan="1">190 (99.5)</td><td char="." align="char" colspan="1" rowspan="1">94 (98.9)</td><td char="." align="char" colspan="1" rowspan="1">96 (100.0)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Number of stents, n (%)</td><td char="." align="char" colspan="1" rowspan="1">1.0 [0.0]</td><td char="." align="char" colspan="1" rowspan="1">1.0 [0.0]</td><td char="." align="char" colspan="1" rowspan="1">1.0 [0.0]</td><td char="." align="char" colspan="1" rowspan="1">0.72</td></tr><tr><td align="left" colspan="1" rowspan="1">Total stent length, mm</td><td char="." align="char" colspan="1" rowspan="1">28.0 [20.0]</td><td char="." align="char" colspan="1" rowspan="1">26.0 [20.0]</td><td char="." align="char" colspan="1" rowspan="1">28.0 [17.0]</td><td char="." align="char" colspan="1" rowspan="1">0.36</td></tr><tr><td align="left" colspan="1" rowspan="1">Stent diameter, mm</td><td char="." align="char" colspan="1" rowspan="1">3.5 [1.0]</td><td char="." align="char" colspan="1" rowspan="1">3.5 [1.0]</td><td char="." align="char" colspan="1" rowspan="1">3.5 [1.0]</td><td char="." align="char" colspan="1" rowspan="1">0.60</td></tr><tr><td align="left" colspan="1" rowspan="1">Polymer type, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">0.88</td></tr><tr><td align="left" colspan="1" rowspan="1">Biodegradable polymer</td><td char="." align="char" colspan="1" rowspan="1">98 (51.3)</td><td char="." align="char" colspan="1" rowspan="1">49 (51.6)</td><td char="." align="char" colspan="1" rowspan="1">49 (51.0)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Durable polymer</td><td char="." align="char" colspan="1" rowspan="1">89 (46.6)</td><td char="." align="char" colspan="1" rowspan="1">43 (45.3)</td><td char="." align="char" colspan="1" rowspan="1">46 (47.9)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Post-dilatation, n (%)</td><td char="." align="char" colspan="1" rowspan="1">160 (83.8%)</td><td char="." align="char" colspan="1" rowspan="1">78 (82.1%)</td><td char="." align="char" colspan="1" rowspan="1">82 (85.4%)</td><td char="." align="char" colspan="1" rowspan="1">0.56</td></tr><tr><td align="left" colspan="1" rowspan="1">Bifurcation lesion, n (%)</td><td char="." align="char" colspan="1" rowspan="1">30 (15.7)</td><td char="." align="char" colspan="1" rowspan="1">12 (12.6)</td><td char="." align="char" colspan="1" rowspan="1">18 (18.8)</td><td char="." align="char" colspan="1" rowspan="1">0.32</td></tr><tr><td align="left" colspan="1" rowspan="1">Multivessel PCI, n (%)</td><td char="." align="char" colspan="1" rowspan="1">19 (9.9)</td><td char="." align="char" colspan="1" rowspan="1">13 (13.7)</td><td char="." align="char" colspan="1" rowspan="1">6 (6.2)</td><td char="." align="char" colspan="1" rowspan="1">0.10</td></tr><tr><td align="left" colspan="1" rowspan="1">GP IIb/IIIa inhibitors, n (%)</td><td char="." align="char" colspan="1" rowspan="1">33 (17.3)</td><td char="." align="char" colspan="1" rowspan="1">16 (16.8)</td><td char="." align="char" colspan="1" rowspan="1">17 (17.7)</td><td char="." align="char" colspan="1" rowspan="1">1.00</td></tr></tbody></table><table-wrap-foot><p>Values are count (percentage), mean (SD), or median [interquartile range]. Multivessel treatment and GP IIb/IIIa are at patient level. All other variables refer to the culprit lesion. Abbreviations: GP: glycoprotein, PCI: percutaneous coronary intervention, TIMI: thrombolysis in myocardial infarction</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec9"><title>OCT findings</title><p id="Par12">OCT findings are shown in Table&#160;<xref rid="Tab3" ref-type="table">3</xref>. Neoatherosclerosis was observed in 13 (6.8%) patients, 4 (4.2%) in the alirocumab group and 9 (9.4%) in the placebo group (<italic toggle="yes">p</italic>&#8201;=&#8201;0.25). There was no difference in the distribution of polymer type of DES between patients with and without neoatherosclerosis (biodegradable polymer: 7.1% vs. 92.9%; durable polymer: 6.7% vs. 93.3%, <italic toggle="yes">p</italic>&#8201;=&#8201;1.00). The frequency of fibroatheroma, fibrocalcific plaque, macrophage, and cholesterol crystal was 5.8%, 1.0%, 1.0%, and 2.1%, respectively, without statistical differences between treatment groups. Among 11 patients with lipid-laden neointima, fibrous cap thickness was significantly greater in the alirocumab group than in the placebo group (217&#8201;&#177;&#8201;123&#160;&#956;m vs. 88&#8201;&#177;&#8201;49&#160;&#956;m, <italic toggle="yes">p</italic>&#8201;=&#8201;0.02). The characteristics of patients with neoatherosclerosis were summarized in Supplementary Table 3. Biochemical measures and intracoronary imaging findings in patients with and without neoatherosclerosis were shown in Supplementary Table 4. Lp(a) levels at baseline (29.9&#8201;&#177;&#8201;39.3&#160;mg/dL vs. 31.1&#8201;&#177;&#8201;39.8&#160;mg/dL, <italic toggle="yes">p</italic>&#8201;=&#8201;0.97) and follow-up (36.4&#8201;&#177;&#8201;46.6&#160;mg/dL vs. 33.5&#8201;&#177;&#8201;45.5&#160;mg/dL, <italic toggle="yes">p</italic>&#8201;=&#8201;0.97) were comparable between patients with and without neoatherosclerosis. Absolute change in serum LDL-C level was &#8722;&#8201;106.5 (&#8722;135.4 to &#8722;77.5) vs. &#8722;104.3 (&#8722;111.0 to &#8722;97.6) mg/dL in patients with vs. without neoatherosclerosis. Figure&#160;<xref rid="Fig1" ref-type="fig">1</xref> shows the frequency of neoatherosclerosis according to mean LDL-C levels in prospective studies.<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>OCT analysis at 1 year</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Overall<break/><italic toggle="yes">n</italic>&#8201;=&#8201;191</th><th align="left" colspan="1" rowspan="1">Alirocumab<break/><italic toggle="yes">n</italic>&#8201;=&#8201;95</th><th align="left" colspan="1" rowspan="1">Placebo<break/><italic toggle="yes">n</italic>&#8201;=&#8201;96</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Duration from implantation, day</td><td align="left" colspan="1" rowspan="1">376 (15)</td><td align="left" colspan="1" rowspan="1">377 (14)</td><td align="left" colspan="1" rowspan="1">374 (16)</td><td char="." align="char" colspan="1" rowspan="1">0.16</td></tr><tr><td align="left" colspan="1" rowspan="1">Neoatherosclerosis, n (%)</td><td align="left" colspan="1" rowspan="1">13 (6.8)</td><td align="left" colspan="1" rowspan="1">4 (4.2)</td><td align="left" colspan="1" rowspan="1">9 (9.4)</td><td char="." align="char" colspan="1" rowspan="1">0.25</td></tr><tr><td align="left" colspan="1" rowspan="1">Fibroatheroma, n (%)</td><td align="left" colspan="1" rowspan="1">11 (5.8)</td><td align="left" colspan="1" rowspan="1">4 (4.2)</td><td align="left" colspan="1" rowspan="1">7 (7.3)</td><td char="." align="char" colspan="1" rowspan="1">0.54</td></tr><tr><td align="left" colspan="1" rowspan="1">*Total length of fibroatheroma, mm</td><td align="left" colspan="1" rowspan="1">5.78 (4.91)</td><td align="left" colspan="1" rowspan="1">4.00 (3.35)</td><td align="left" colspan="1" rowspan="1">6.80 (5.59)</td><td char="." align="char" colspan="1" rowspan="1">0.32</td></tr><tr><td align="left" colspan="1" rowspan="1">*Maximum lipid arc, degree</td><td align="left" colspan="1" rowspan="1">173 (73)</td><td align="left" colspan="1" rowspan="1">155 (38)</td><td align="left" colspan="1" rowspan="1">184 (89)</td><td char="." align="char" colspan="1" rowspan="1">0.79</td></tr><tr><td align="left" colspan="1" rowspan="1">*Minimum cap thickness, &#181;m</td><td align="left" colspan="1" rowspan="1">135 (101)</td><td align="left" colspan="1" rowspan="1">217 (123)</td><td align="left" colspan="1" rowspan="1">88 (49)</td><td char="." align="char" colspan="1" rowspan="1"><bold>0.02</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Fibrocalcified, n (%)</td><td align="left" colspan="1" rowspan="1">2 (1.0)</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1">2 (2.1)</td><td char="." align="char" colspan="1" rowspan="1">0.50</td></tr><tr><td align="left" colspan="1" rowspan="1">Macrophage accumulations, n (%)</td><td align="left" colspan="1" rowspan="1">2 (1.0)</td><td align="left" colspan="1" rowspan="1">1 (1.1)</td><td align="left" colspan="1" rowspan="1">1 (1.0)</td><td char="." align="char" colspan="1" rowspan="1">1.00</td></tr><tr><td align="left" colspan="1" rowspan="1">In-stent cholesterol crystal, n (%)</td><td align="left" colspan="1" rowspan="1">4 (2.1)</td><td align="left" colspan="1" rowspan="1">1 (1.1)</td><td align="left" colspan="1" rowspan="1">3 (3.1)</td><td char="." align="char" colspan="1" rowspan="1">0.62</td></tr><tr><td align="left" colspan="1" rowspan="1">Other findings, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Thrombus</td><td align="left" colspan="1" rowspan="1">2 (1.0)</td><td align="left" colspan="1" rowspan="1">2 (2.1)</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td char="." align="char" colspan="1" rowspan="1">0.50</td></tr><tr><td align="left" colspan="1" rowspan="1">Microvessel</td><td align="left" colspan="1" rowspan="1">76 (39.8)</td><td align="left" colspan="1" rowspan="1">39 (41.1)</td><td align="left" colspan="1" rowspan="1">37 (38.5)</td><td char="." align="char" colspan="1" rowspan="1">0.88</td></tr><tr><td align="left" colspan="1" rowspan="1">Lesion level analysis</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Analyzed stent length, mm</td><td align="left" colspan="1" rowspan="1">31.1 (14.1)</td><td align="left" colspan="1" rowspan="1">30.1 (13.6)</td><td align="left" colspan="1" rowspan="1">32.0 (14.6)</td><td char="." align="char" colspan="1" rowspan="1">0.45</td></tr><tr><td align="left" colspan="1" rowspan="1">Minimal lumen area, mm<sup>2</sup></td><td align="left" colspan="1" rowspan="1">4.82 (2.21)</td><td align="left" colspan="1" rowspan="1">5.09 (2.32)</td><td align="left" colspan="1" rowspan="1">4.55 (2.07)</td><td char="." align="char" colspan="1" rowspan="1">0.09</td></tr><tr><td align="left" colspan="1" rowspan="1">Minimal stent area, mm<sup>2</sup></td><td align="left" colspan="1" rowspan="1">6.05 (2.45)</td><td align="left" colspan="1" rowspan="1">6.21 (2.39)</td><td align="left" colspan="1" rowspan="1">5.90 (2.51)</td><td char="." align="char" colspan="1" rowspan="1">0.37</td></tr><tr><td align="left" colspan="1" rowspan="1">Cross section level analysis</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Analyzed cross section per lesion, n (%)</td><td align="left" colspan="1" rowspan="1">78 (35)</td><td align="left" colspan="1" rowspan="1">77 (35)</td><td align="left" colspan="1" rowspan="1">80 (36)</td><td char="." align="char" colspan="1" rowspan="1">0.53</td></tr><tr><td align="left" colspan="1" rowspan="1">Mean lumen area, mm<sup>2</sup></td><td align="left" colspan="1" rowspan="1">6.98 (2.82)</td><td align="left" colspan="1" rowspan="1">7.13 (2.71)</td><td align="left" colspan="1" rowspan="1">6.83 (2.93)</td><td char="." align="char" colspan="1" rowspan="1">0.28</td></tr><tr><td align="left" colspan="1" rowspan="1">Mean stent area, mm<sup>2</sup></td><td align="left" colspan="1" rowspan="1">8.06 (2.97)</td><td align="left" colspan="1" rowspan="1">8.12 (2.69)</td><td align="left" colspan="1" rowspan="1">8.00 (3.23)</td><td char="." align="char" colspan="1" rowspan="1">0.57</td></tr><tr><td align="left" colspan="1" rowspan="1">Neointimal area, mm<sup>2</sup></td><td align="left" colspan="1" rowspan="1">1.14 (0.85)</td><td align="left" colspan="1" rowspan="1">1.07 (0.73)</td><td align="left" colspan="1" rowspan="1">1.20 (0.96)</td><td char="." align="char" colspan="1" rowspan="1">0.60</td></tr><tr><td align="left" colspan="1" rowspan="1">Malapposed area, mm<sup>2</sup></td><td align="left" colspan="1" rowspan="1">0.05 (0.20)</td><td align="left" colspan="1" rowspan="1">0.07 (0.25)</td><td align="left" colspan="1" rowspan="1">0.03 (0.12)</td><td char="." align="char" colspan="1" rowspan="1">0.40</td></tr><tr><td align="left" colspan="1" rowspan="1">Strut level analysis</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Analyzed struts per lesion, n (%)</td><td align="left" colspan="1" rowspan="1">762 (364)</td><td align="left" colspan="1" rowspan="1">744 (353)</td><td align="left" colspan="1" rowspan="1">781 (375)</td><td char="." align="char" colspan="1" rowspan="1">0.48</td></tr><tr><td align="left" colspan="1" rowspan="1">Mean neointimal thickness, &#181;m</td><td align="left" colspan="1" rowspan="1">145 (88)</td><td align="left" colspan="1" rowspan="1">136 (71)</td><td align="left" colspan="1" rowspan="1">151 (101)</td><td char="." align="char" colspan="1" rowspan="1">0.45</td></tr><tr><td align="left" colspan="1" rowspan="1">Rate of uncovered struts, %</td><td align="left" colspan="1" rowspan="1">2.7 (3.9)</td><td align="left" colspan="1" rowspan="1">3.1 (4.5)</td><td align="left" colspan="1" rowspan="1">2.3 (3.3)</td><td char="." align="char" colspan="1" rowspan="1">0.45</td></tr><tr><td align="left" colspan="1" rowspan="1">Rate of malapposed struts, %</td><td align="left" colspan="1" rowspan="1">0.7 (2.4)</td><td align="left" colspan="1" rowspan="1">0.9 (2.8)</td><td align="left" colspan="1" rowspan="1">0.5 (2.1)</td><td char="." align="char" colspan="1" rowspan="1">0.27</td></tr><tr><td align="left" colspan="1" rowspan="1">Incomplete apposition distance, &#181;m</td><td align="left" colspan="1" rowspan="1">3.66 (12.04)</td><td align="left" colspan="1" rowspan="1">4.73 (13.93)</td><td align="left" colspan="1" rowspan="1">2.61 (9.77)</td><td char="." align="char" colspan="1" rowspan="1">0.49</td></tr></tbody></table><table-wrap-foot><p>Values are count (percentage) or mean (SD). Abbreviations: OCT: optical coherence tomography. *calculated across 11 patients</p></table-wrap-foot></table-wrap><fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Frequency of neoatherosclerosis according to mean LDL-C levels in prospective studies. Bubble plot showing the frequency of neoatherosclerosis (y-axis) in comparison to mean on-treatment LDL-C level (x-axis). Bubble size is proportional to the overall number of patients (PACMAN-AMI alirocumab group: 95, PACMAN-AMI Placebo group: 96, CONNECT patients achieving target LDL-C level: 98, CONNECT patients not achieving target LDL-C level: 80, TRANSFORM-OCT: 87, Sakai_J Clin Lipidol 2023: 114). BP: biodegradable polymer, DP: durable polymer, EES: everolimus-eluting stents, LDL-C: low density lipoprotein cholesterol, ZES: zotarolimus-eluting stents</p></caption><graphic id="MO2" position="float" orientation="portrait" xlink:href="10554_2025_3472_Fig1_HTML.jpg"/></fig></p><p id="Par13">At a cross sectional level, there were no differences in the frequency of cross sections with uncovered struts (15.0 vs. 12.13%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.57) and malapposed struts (4.0 vs. 1.7%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.24), and neointimal area (1.07&#8201;&#177;&#8201;0.73 vs. 1.20&#8201;&#177;&#8201;0.96 mm<sup>2</sup>, <italic toggle="yes">p</italic>&#8201;=&#8201;0.60) between the two groups (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). Supplementary Fig. 2&#160;shows the correlation between neointimal area and absolute change in LDL-C, and Supplementary Fig.&#160;3 shows the correlation between percentage of uncovered struts and absolute change in LDL-C. At a strut level, the percentage of uncovered struts (3.1 vs. 2.3%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.45), the percentage of malapposed struts (0.9 vs. 0.5%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.27) and neointimal thickness (136 vs. 151&#160;&#956;m, <italic toggle="yes">p</italic>&#8201;=&#8201;0.45) were comparable between two groups (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). Patients with neoatherosclerosis had greater neointimal area (2.11&#8201;&#177;&#8201;1.08 vs. 1.06&#8201;&#177;&#8201;0.79 mm<sup>2</sup>) and greater neointimal thickness (241&#8201;&#177;&#8201;97 vs. 137&#8201;&#177;&#8201;83&#160;&#956;m) compared with those without (Supplementary Table 5).</p></sec><sec id="Sec10"><title>Clinical outcomes</title><p id="Par14">Supplementary Table 6 shows the incidence of the revascularization at 1 year. Revascularization was performed in 35 patients (18.3%). Among them, 11 patients (5.8%) underwent ischemia-driven target lesion revascularization, 2 (15.4%) with neoatherosclerosis and 9 (5.1%) without neoatherosclerosis. Ischemia-driven non-target lesion revascularization was performed in 19 patients (9.9%), 1 (7.7%) in patients with neoatherosclerosis and 18 (10.1%) in patients without neoatherosclerosis.</p></sec></sec><sec id="Sec11"><title>Discussion</title><p id="Par15">This is the first study to investigate the effect of very low LDL-C level achieved by alirocumab on neoatherosclerosis formation and vessel healing among AMI patients undergoing PCI with current generation DES. The main findings of the present study, based on OCT performed in the stented culprit lesion 1 year after primary PCI, are: (1) there were no significant differences in the frequency of neoatherosclerosis between the alirocumab and placebo groups in the context of a background high-intensity statin treatment in both treatment arms (rosuvastatin 20&#160;mg). However, neoatheroma in the alirocumab group was more stable as suggested by a significantly greater minimal fibrous cap thickness, (2) the degree of vessel healing represented by neointimal growth, strut coverage, and strut apposition did not significantly differ between the treatment groups at 1 year following primary PCI.</p><sec id="Sec12"><title>Frequency of neoatherosclerosis</title><p id="Par16">Although there are several relevant differences in pathogenic mechanisms between in-stent neoatherosclerosis and native atherosclerosis, lipid diffusion and inflammatory cell migration through the endothelium are considered common pathways of atherosclerosis formation for both disease entities. Previous retrospective observational studies have demonstrated a significant correlation between the serum LDL-C level and the frequency of neoatherosclerosis [<xref ref-type="bibr" rid="CR10">10</xref>&#8211;<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. The substudy of the CONNECT trial also demonstrated that neoatherosclerosis was less frequent in STEMI patients who achieved guideline-endorsed LDL-C levels and received high-intensity statin therapy 3 years after implantation of current generation DES [<xref ref-type="bibr" rid="CR21">21</xref>]. In the current study, the frequency of neoatherosclerosis was numerically lower in the alirocumab group (4.2% vs. 9.4%), but there was no significant difference between groups despite very low LDL-C levels achieved in the alirocumab group (mean 23.2&#160;mg/dL vs. 73.5&#160;mg/dL). A potential explanation may be the lack of power (i.e. type II error) in view of only 13 patients with neoatherosclerosis at 1 year. The relatively short follow-up period of 1 year in our pre-specified sub-study may at least partly contribute to small number of neoatherosclerosis formation. Another explanation may be the initiation of high-intensity statin therapy (rosuvastatin 20&#160;mg) in both groups from the first day after primary PCI, which was not the case in previous studies. Statins not only decrease LDL-C level but also reduce inflammation, which can lead to endothelial cell activation and dysfunction [<xref ref-type="bibr" rid="CR22">22</xref>] and thus result in neoatherosclerosis formation. The level of high sensitive C-reactive protein (hsCRP) was reportedly associated with the accumulation of lipids within the neointima [<xref ref-type="bibr" rid="CR10">10</xref>]. Unlike statins, PSCK9i have little no effect on inflammation [<xref ref-type="bibr" rid="CR23">23</xref>] and accordingly, the on-treatment hsCRP level was similar in both treatment groups in our study (2.0 vs. 2.5&#160;mg/L, <italic toggle="yes">p</italic>&#8201;=&#8201;0.71). Interestingly, neoatheroma in the alirocumab group had a significantly greater minimal fibrous cap thickness. This finding may suggest that intensive lipid-lowering afforded by alirocumab resulted in more stable neoatheroma, along the lines of the effects of alirocumab observed in the main study investigating native atherosclerosis [<xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par17">The frequency of neoatherosclerosis in the alirocumab group in the current study (4.2%) appeared to be among the lowest ever reported compared with previous prospective observational studies that typically found neoatherosclerosis in 11.4&#8211;15.9% between 1 and 3 years with on-treatment LDL-C levels between 63 and 80&#160;mg/dL [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>] (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). Moreover, the frequency of neoatherosclerosis in the placebo group of the present study (9.4%) was also numerically lower compared to that reported in previous studies despite a similar on-treatment LDL-C level. The lower frequency in the current study may be explained by the routine use of high-intensity statin therapy, stent types, and clinical presentation. In particular, a previous pathological study reported that neointimal thickness in culprit site of AMI was significantly smaller than in coronary lesions in stable patients [<xref ref-type="bibr" rid="CR9">9</xref>]. Given the pathological role of in-stent neointima as a basis for neoatherosclerosis formation, the lower frequency of neoatherosclerosis might be attributed to smaller neointimal tissue in the AMI culprit lesions in the current study.</p><p id="Par18">Interestingly, we noted some patients with neoatherosclerosis formation within 12 months with very low on treatment LDL-C values (Supplementary Table 3), i.e. 3 patients with &lt;&#8201;20&#160;mg/dL. This underlines that on-treatment LDL-C should not be considered as an isolated driver of neoatherosclerosis. In these patients, hsCRP levels at follow-up were 0, 0, and 0.8&#160;mg/L, respectively. These three patients suggest that other, incompletely understood mechanisms unrelated to LDL-C and inflammation may come into play.</p></sec><sec id="Sec13"><title>Neointimal growth and strut malapposition</title><p id="Par19">In the current study, there was no significant difference in the degree of neointimal hyperplasia, strut coverage, and strut apposition. Although there have been potential concerns of late-acquired malapposition due to pronounced plaque regression induced by intensive LDL-C lowering with alirocumab, reassuringly, we did not observe such a phenomenon in the current analysis showing a low and similar frequency of malapposed and uncovered struts in both treatment groups and no correlation with on treatment LDL-C. This represents a reassuring finding with respect to the safety of DES in patients receiving intensive lipid lowering therapy.</p><p id="Par20">In contrast to our findings, a previous observational OCT study in South Korea investigating the effect of on treatment LDL-C level on neointimal hyperplasia among 218 patients treated with DES has demonstrated that neointimal tissue growth from 6 to 18 months was more suppressed in patients with a lower LDL-C level (58&#8201;&#177;&#8201;11&#160;mg/dL) compared with those with a higher LDL-C level (92&#8201;&#177;&#8201;18&#160;mg/dL) (change in neointimal area: 0.2 vs. 0.4mm<sup>2</sup>, <italic toggle="yes">p</italic>&#8201;=&#8201;0.01) [<xref ref-type="bibr" rid="CR27">27</xref>]. The potential reasons for inconsistent results include the observational versus randomized controlled design and the study duration.</p></sec><sec id="Sec14"><title>Clinical implication</title><p id="Par21">Neoatherosclerosis is a predominant mechanism underlying late stent failure contributing to at least 30&#8211;40% of failure cases occurring beyond the first year after revascularization. Moreover, previous studies have demonstrated its prognostic significance for adverse cardiovascular events, including cardiac death and target lesion revascularization [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. Although Lp(a) levels were previously associated with the occurrence of neoatherosclerosis in one observational study [<xref ref-type="bibr" rid="CR29">29</xref>], we did not find such an association. More and larger studies are needed that correlate Lp(a) baseline levels with neoatherosclerosis formation. Several clinical trials investigating the effect of Lp(a) lowering on cardiovascular outcomes are currently ongoing and depending on the results, future studies should also focus on the prevention of neoatherosclerosis. The effects of PCSK9 inhibitors on stent-related outcomes remain underexplored. In a substudy of the FOURIER trial involving patients with prior PCI and followed for 2.2 years, there were significantly less revascularizations of de novo lesions, however, no significant difference was observed between evolocumab and placebo treated groups regarding the incidence of PCI for in-stent restenosis (2.0 vs. 2.3%, HR 0.84 (0.69&#8211;1.03) or stent thrombosis (0.4 vs. 0.5%, HR 0.81 (0.52&#8211;1.25). One limitation of this study is that neoatherosclerosis-related revascularizations usually occur far beyond the first year after stent implantation [<xref ref-type="bibr" rid="CR30">30</xref>]. Further studies are warranted to elucidate the impact of intensive lipid-lowering therapy with PCSK9 inhibitors on stent-related outcomes.</p></sec><sec id="Sec15"><title>Limitations</title><p id="Par22">The present study has several limitations. First, the lack of significant differences between groups may be attributable to the lack of power (i.e., type II error) due to small sample size and low frequency of neoatherosclerosis. Second, OCT imaging for the culprit stents was not performed in all patients enrolled into the PACMAN-AMI trial, which may lead to patient selection bias. However, no differences in key baseline patient, lesion and procedural characteristics between patients with and without OCT imaging at 1 year were observed (Supplementary Table 2). Third, the follow-up period of 1 year was relatively short to evaluate the occurrence of neoatherosclerosis, which can emerge consistently after 1 year and is the primary mechanism of very late (&gt;&#8201;1 year) stent failure. Fourth, OCT findings at baseline including plaque morphology of the culprit lesion and acute stent results (i.e. stent expansion, strut apposition), known predictors of stent healing and neoatherosclerosis formation, were not available in the current study [<xref ref-type="bibr" rid="CR19">19</xref>]. Although patients were randomly assigned to the alirocumab group and the placebo group, the potential influence of these confounding factors on the frequency of neoatherosclerosis cannot be excluded. Fifth, although all patients were treated with current generation DES in the current study, the choice of stent type was left at the operator&#8217;s discretion. Stent type was reported in Supplementary Table 7. Previous studies have reported that stent type was significantly associated with the occurrence of neoatherosclerosis [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR31">31</xref>&#8211;<xref ref-type="bibr" rid="CR33">33</xref>]. Sixth, despite its high spatial resolution, OCT cannot reliably distinguish healthy neointima from fibrin and thrombus [<xref ref-type="bibr" rid="CR34">34</xref>].</p></sec></sec><sec id="Sec16"><title>Conclusion</title><p id="Par23">Among AMI patients undergoing PCI of the culprit lesion with newer generation DES, there was no significant impact of alirocumab on the frequency of neoatherosclerosis and vessel healing at 1 year. The observed numerical difference and the finding of more stable neoatheroma in favor of alirocumab require further investigation in larger studies with extended follow-up.</p></sec><sec id="Sec17" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xlink:href="10554_2025_3472_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors thank the staff personnel of the cardiovascular department at participating sites for their invaluable support.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Ryota Kakizaki, Yasushi Ueki, Hiroki Shibutani, Flavio G. Biccir&#232;, Tatsuhiko Otsuka, Jonas D. H&#228;ner, Jacob L&#248;nborg, Christoph Kaiser, Juan F. Iglesias, Anna S. Ondracek, David Spirk, George C. M. Siontis, Joost Daemen, Thomas Engstr&#248;m, Irene M. Lang, and Lorenz R&#228;ber. Statistical analysis was done by Sylvain Losdat. The first draft of the manuscript was written by Ryota Kakizaki, Yasushi Ueki, and Konstantinos C. Koskinas. All authors commented on previous versions of the manuscript, and all read and approved the final version. Lorenz R&#228;ber was responsible for supervision, conceptualization, and project administration.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by University of Bern. The main PACMAN-AMI trial was funded by Sanofi, Regeneron, and Infraredx. Regeneron provided alirocumab and placebo free of charge. The current sub-study was conducted in an independent academic setting and funded by intramural grants of Bern University Hospital.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data set will be available from the corresponding author on reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar2" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par24">Dr. Kakizaki reported receiving consulting fee from Infraredx USA, speaker fee from Abbott Medical Japan, Boston Scientific Japan, Philips Japan, Orbusneich Medical, manuscript writing fee from Orbusneich Medical and Philips Japan, Support for attending meetings and travel from OM Pharma outside the submitted work. Dr. Ueki reported receiving grants from Astellas Pharma, personal fees from Abbott Vascular, Amgen, Bayer, Daiichi Sankyo, Kowa, NIPRO, and Novartis, outside the submitted work. Dr. Koskinas reported receiving grants from Sanofi, Regeneron, and Infraredx during the conduct of the study and personal fees from Amgen and Daiichi Sankyo outside the submitted work. No other disclosures were reported. Dr. Losdat is employed by the DCR Bern, University of Bern, which has a staff policy of not accepting honoraria or consultancy fees. However, CTU Bern is involved in design, conduct, or analysis of clinical studies funded by not-for-profit and for-profit organizations. In particular, pharmaceutical and medical device companies provide direct funding to some of these studies. (for an up-to-date list of DCR Bern&#8217;s conflicts of interest, see <ext-link ext-link-type="uri" xlink:href="https://dcr.unibe.ch/services/terms__conditions/index_eng.html">https://dcr.unibe.ch/services/terms__conditions/index_eng.html</ext-link>) Dr. Biccir&#232; reported receiving consulting fee from Abbott, speaker fee from Abbott, Ultragenyx, and Sanofi outside the submitted work. Dr. Otsuka reported receiving speaker fees from Amgen, Nipro, and Kowa. Dr. L&#248;nborg reported receiving grants from Boston Scientific, consulting fees from Boston Scientific, speakers fee from Abbott and Boston Scientific, and Support for attending meetings and travel from Abbott, and owns stock in Novo Nordisk. Dr. Kaiser reported receiving consulting fees from Unimedtec Switzerland and Swiss office of federal health. Dr. Iglesias reported receiving grants from Biotronik, Concept Medical, and Terumo, consulting fees from Medtronic, Biotronik, Cordis, and ReCor Medical, speakers fees from Medtronic, Penumbra, Biotronik, Concept Medical, BRISTOL MYERS SQUIBB/PFIZER, Cordis, and Recor Medical, Support for attending meetings and travel from Biotronik, and participating Data Safety Monitoring Board of the CoSTAR trial (<ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT04870424">NCT04870424</ext-link>). Dr. Spirk reported receiving personal fees from Sanofi-Aventis (Switzerland) at the time of study conduct and Cook Medical outside the submitted work. Dr. Daemen reported receiving institutional grant/research support from Abbott Vascular, Boston Scientific, ACIST Medical, Medtronic, Pie Medical, and ReCor medical, and consultancy and speaker fees from Abbott Vascular, Abiomed, ACIST medical, Boston Scientific, Cardialysis BV, CardiacBooster, Kaminari Medical, ReCor Medical, PulseCath, Pie Medical, Sanofi, Siemens Health Care and Medtronic. Dr Engstr&#248;m reported advisory board fees from Abbott and Novo Nordisk and speaker fees from Boston Scientific outside the submitted work. Dr. Lang has relationships with drug companies including AOP-Health, Actelion-Janssen, MSD, United Therapeutics, Pulnovo, Medtronic, INARI, Neutrolis and Sanofi. In addition to being investigator in trials involving these companies, relationships include consultancy service, research grants, and membership of scientific advisory boards. Dr. R&#228;ber reported receiving grants from Sanofi, Regeneron, and Infraredx to Inselspital and speaker fees from Sanofi during the conduct of the study and grants from Abbott, Heartflow, Boston Scientific, and Biotronik to Inselspital and grants from Abbott, Amgen, AstraZeneca, Occlutech, Sanofi, Canon, and Medtronic for speaker and consultation fees outside the submitted work.</p></notes><notes id="FPar3"><title>Ethical approval</title><p id="Par25">This study was performed in line with the principles of the Declaration of Helsinki, and the study was approved by the ethical committee at each site.</p></notes><notes id="FPar4"><title>Consent to participate</title><p id="Par26">Informed consent was obtained from all individual participants included in the study, all patients provided written informed consent.</p></notes><notes id="FPar5"><title>Consent to publish</title><p id="Par27">All participants provided informed consent, acknowledging that their health-related and personal information (and samples) would be shared only in encrypted form for research purposes, including international collaboration, and that their names would not be published in any form.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piccolo</surname><given-names>R</given-names></name><name name-style="western"><surname>Bonaa</surname><given-names>KH</given-names></name><name name-style="western"><surname>Efthimiou</surname><given-names>O</given-names></name><name name-style="western"><surname>Varenne</surname><given-names>O</given-names></name><name name-style="western"><surname>Baldo</surname><given-names>A</given-names></name><etal/></person-group><article-title>Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials</article-title><source>Lancet Jun</source><year>2019</year><volume>22</volume><issue>10190</issue><fpage>2503</fpage><lpage>2510</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(19)30474-X</pub-id><pub-id pub-id-type="pmid">31056295</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Piccolo R, Bonaa KH, Efthimiou O, Varenne O, Baldo A et al (2019) Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials. Lancet Jun 22(10190):2503&#8211;2510. 10.1016/S0140-6736(19)30474-X<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(19)30474-X</pub-id><pub-id pub-id-type="pmid">31056295</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>JM</given-names></name><name name-style="western"><surname>Park</surname><given-names>KW</given-names></name><name name-style="western"><surname>Han</surname><given-names>JK</given-names></name><name name-style="western"><surname>Yang</surname><given-names>HM</given-names></name><name name-style="western"><surname>Kang</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Three-year patient-related and stent-related outcomes of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice (from the multicenter prospective EXCELLENT and RESOLUTE-Korea Registries)</article-title><source>Am J Cardiol Nov</source><year>2014</year><volume>1</volume><issue>9</issue><fpage>1329</fpage><lpage>1338</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2014.07.065</pub-id><pub-id pub-id-type="pmid">25217457</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Lee JM, Park KW, Han JK, Yang HM, Kang HJ et al (2014) Three-year patient-related and stent-related outcomes of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice (from the multicenter prospective EXCELLENT and RESOLUTE-Korea Registries). Am J Cardiol Nov 1(9):1329&#8211;1338. 10.1016/j.amjcard.2014.07.065<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amjcard.2014.07.065</pub-id><pub-id pub-id-type="pmid">25217457</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Camenzind</surname><given-names>E</given-names></name><name name-style="western"><surname>Wijns</surname><given-names>W</given-names></name><name name-style="western"><surname>Mauri</surname><given-names>L</given-names></name><name name-style="western"><surname>Kurowski</surname><given-names>V</given-names></name><name name-style="western"><surname>Parikh</surname><given-names>K</given-names></name><etal/></person-group><article-title>Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial</article-title><source>Lancet Oct</source><year>2012</year><volume>20</volume><issue>9851</issue><fpage>1396</fpage><lpage>1405</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)61336-1</pub-id><pub-id pub-id-type="pmid">22951082</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Camenzind E, Wijns W, Mauri L, Kurowski V, Parikh K et al (2012) Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet Oct 20(9851):1396&#8211;1405. 10.1016/S0140-6736(12)61336-1<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(12)61336-1</pub-id><pub-id pub-id-type="pmid">22951082</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zanchin</surname><given-names>C</given-names></name><name name-style="western"><surname>Ueki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zanchin</surname><given-names>T</given-names></name><name name-style="western"><surname>Haner</surname><given-names>J</given-names></name><name name-style="western"><surname>Otsuka</surname><given-names>T</given-names></name><etal/></person-group><article-title>Everolimus-Eluting biodegradable polymer versus Everolimus-Eluting durable polymer stent for coronary revascularization in routine clinical practice</article-title><source>JACC Cardiovasc Interv Sep</source><year>2019</year><volume>9</volume><issue>17</issue><fpage>1665</fpage><lpage>1675</lpage><pub-id pub-id-type="doi">10.1016/j.jcin.2019.04.046</pub-id><pub-id pub-id-type="pmid">31422088</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Zanchin C, Ueki Y, Zanchin T, Haner J, Otsuka T et al (2019) Everolimus-Eluting biodegradable polymer versus Everolimus-Eluting durable polymer stent for coronary revascularization in routine clinical practice. JACC Cardiovasc Interv Sep 9(17):1665&#8211;1675. 10.1016/j.jcin.2019.04.046<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jcin.2019.04.046</pub-id><pub-id pub-id-type="pmid">31422088</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takano</surname><given-names>M</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Inami</surname><given-names>S</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>D</given-names></name><name name-style="western"><surname>Ohba</surname><given-names>T</given-names></name><etal/></person-group><article-title>Appearance of lipid-laden intima and neovascularization after implantation of bare-metal stents extended late-phase observation by intracoronary optical coherence tomography</article-title><source>J Am Coll Cardiol Dec</source><year>2009</year><volume>29</volume><issue>1</issue><fpage>26</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2009.08.032</pub-id><pub-id pub-id-type="pmid">20117359</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Takano M, Yamamoto M, Inami S, Murakami D, Ohba T et al (2009) Appearance of lipid-laden intima and neovascularization after implantation of bare-metal stents extended late-phase observation by intracoronary optical coherence tomography. J Am Coll Cardiol Dec 29(1):26&#8211;32. 10.1016/j.jacc.2009.08.032<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2009.08.032</pub-id><pub-id pub-id-type="pmid">20117359</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taniwaki</surname><given-names>M</given-names></name><name name-style="western"><surname>Radu</surname><given-names>MD</given-names></name><name name-style="western"><surname>Zaugg</surname><given-names>S</given-names></name><name name-style="western"><surname>Amabile</surname><given-names>N</given-names></name><name name-style="western"><surname>Garcia-Garcia</surname><given-names>HM</given-names></name><etal/></person-group><article-title>Mechanisms of very late Drug-Eluting stent thrombosis assessed by optical coherence tomography</article-title><source>Circulation Feb</source><year>2016</year><volume>16</volume><issue>7</issue><fpage>650</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.115.019071</pub-id><pub-id pub-id-type="pmid">26762519</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Taniwaki M, Radu MD, Zaugg S, Amabile N, Garcia-Garcia HM et al (2016) Mechanisms of very late Drug-Eluting stent thrombosis assessed by optical coherence tomography. Circulation Feb 16(7):650&#8211;660. 10.1161/CIRCULATIONAHA.115.019071<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.115.019071</pub-id><pub-id pub-id-type="pmid">26762519</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Nakamura D, Attizzani GF, Toma C, Sheth T, Wang W et al (2016) Failure mechanisms and neoatherosclerosis patterns in very late Drug-Eluting and Bare-Metal stent thrombosis. Circ Cardiovasc Interv Sep 9(9). 10.1161/CIRCINTERVENTIONS.116.003785<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCINTERVENTIONS.116.003785</pub-id><pub-id pub-id-type="pmid">27582113</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawai</surname><given-names>K</given-names></name><name name-style="western"><surname>Virmani</surname><given-names>R</given-names></name><name name-style="western"><surname>Finn</surname><given-names>AV</given-names></name></person-group><article-title>In-Stent restenosis</article-title><source>Interv Cardiol Clin Oct</source><year>2022</year><volume>11</volume><issue>4</issue><fpage>429</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1016/j.iccl.2022.02.005</pub-id><pub-id pub-id-type="pmid">36243488</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Kawai K, Virmani R, Finn AV (2022) In-Stent restenosis. Interv Cardiol Clin Oct 11(4):429&#8211;443. 10.1016/j.iccl.2022.02.005<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.iccl.2022.02.005</pub-id><pub-id pub-id-type="pmid">36243488</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakazawa</surname><given-names>G</given-names></name><name name-style="western"><surname>Finn</surname><given-names>AV</given-names></name><name name-style="western"><surname>Joner</surname><given-names>M</given-names></name><name name-style="western"><surname>Ladich</surname><given-names>E</given-names></name><name name-style="western"><surname>Kutys</surname><given-names>R</given-names></name><etal/></person-group><article-title>Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study</article-title><source>Circulation Sep</source><year>2008</year><volume>9</volume><issue>11</issue><fpage>1138</fpage><lpage>1145</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.762047</pub-id><pub-id pub-id-type="pmid">18725485</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R et al (2008) Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation Sep 9(11):1138&#8211;1145. 10.1161/CIRCULATIONAHA.107.762047<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.107.762047</pub-id><pub-id pub-id-type="pmid">18725485</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Kuroda M, Otake H, Shinke T, Takaya T, Nakagawa M et al (2016) The impact of in-stent neoatherosclerosis on long-term clinical outcomes: an observational study from the Kobe University Hospital optical coherence tomography registry. <italic toggle="yes">EuroIntervention</italic>. Dec 10.;12(11):e1366-e1374. 10.4244/EIJY15M12_05<pub-id pub-id-type="doi" assigning-authority="pmc">10.4244/EIJY15M12_05</pub-id><pub-id pub-id-type="pmid">26690315</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Matsumura</surname><given-names>M</given-names></name><name name-style="western"><surname>Mintz</surname><given-names>GS</given-names></name><name name-style="western"><surname>Noguchi</surname><given-names>M</given-names></name><name name-style="western"><surname>Fujimura</surname><given-names>T</given-names></name><etal/></person-group><article-title>Prevalence and impact of neoatherosclerosis on clinical outcomes after percutaneous treatment of Second-Generation Drug-Eluting stent restenosis</article-title><source>Circ Cardiovasc Interv Sep</source><year>2022</year><volume>15</volume><issue>9</issue><fpage>e011693</fpage><pub-id pub-id-type="doi">10.1161/CIRCINTERVENTIONS.121.011693</pub-id><pub-id pub-id-type="pmid">36126137</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Chen Z, Matsumura M, Mintz GS, Noguchi M, Fujimura T et al (2022) Prevalence and impact of neoatherosclerosis on clinical outcomes after percutaneous treatment of Second-Generation Drug-Eluting stent restenosis. Circ Cardiovasc Interv Sep 15(9):e011693. 10.1161/CIRCINTERVENTIONS.121.011693<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCINTERVENTIONS.121.011693</pub-id><pub-id pub-id-type="pmid">36126137</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimono</surname><given-names>H</given-names></name><name name-style="western"><surname>Kajiya</surname><given-names>T</given-names></name><name name-style="western"><surname>Takaoka</surname><given-names>J</given-names></name><name name-style="western"><surname>Miyamura</surname><given-names>A</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>T</given-names></name><etal/></person-group><article-title>Characteristics of recurrent in-stent restenosis after second- and third-generation drug-eluting stent implantation</article-title><source>Coron Artery Dis Jan</source><year>2021</year><volume>32</volume><issue>1</issue><fpage>36</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1097/MCA.0000000000000945</pub-id><pub-id pub-id-type="pmid">32826448</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Shimono H, Kajiya T, Takaoka J, Miyamura A, Inoue T et al (2021) Characteristics of recurrent in-stent restenosis after second- and third-generation drug-eluting stent implantation. Coron Artery Dis Jan 32(1):36&#8211;41. 10.1097/MCA.0000000000000945<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MCA.0000000000000945</pub-id><pub-id pub-id-type="pmid">32826448</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwartz</surname><given-names>GG</given-names></name><name name-style="western"><surname>Steg</surname><given-names>PG</given-names></name><name name-style="western"><surname>Szarek</surname><given-names>M</given-names></name><name name-style="western"><surname>Bhatt</surname><given-names>DL</given-names></name><name name-style="western"><surname>Bittner</surname><given-names>VA</given-names></name><etal/></person-group><article-title>Alirocumab and cardiovascular outcomes after acute coronary syndrome</article-title><source>N Engl J Med Nov</source><year>2018</year><volume>29</volume><issue>22</issue><fpage>2097</fpage><lpage>2107</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1801174</pub-id><pub-id pub-id-type="pmid">30403574</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA et al (2018) Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med Nov 29(22):2097&#8211;2107. 10.1056/NEJMoa1801174<pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1801174</pub-id><pub-id pub-id-type="pmid">30403574</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raber</surname><given-names>L</given-names></name><name name-style="western"><surname>Ueki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Otsuka</surname><given-names>T</given-names></name><name name-style="western"><surname>Losdat</surname><given-names>S</given-names></name><name name-style="western"><surname>Haner</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Effect of Alirocumab added to High-Intensity Statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial</article-title><source>JAMA May</source><year>2022</year><volume>10</volume><issue>18</issue><fpage>1771</fpage><lpage>1781</lpage><pub-id pub-id-type="doi">10.1001/jama.2022.5218</pub-id><pub-id pub-id-type="pmcid">PMC8978048</pub-id><pub-id pub-id-type="pmid">35368058</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Raber L, Ueki Y, Otsuka T, Losdat S, Haner JD et al (2022) Effect of Alirocumab added to High-Intensity Statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. JAMA May 10(18):1771&#8211;1781. 10.1001/jama.2022.5218<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2022.5218</pub-id><pub-id pub-id-type="pmcid">PMC8978048</pub-id><pub-id pub-id-type="pmid">35368058</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zanchin</surname><given-names>C</given-names></name><name name-style="western"><surname>Koskinas</surname><given-names>KC</given-names></name><name name-style="western"><surname>Ueki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Losdat</surname><given-names>S</given-names></name><name name-style="western"><surname>Haner</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Effects of the PCSK9 antibody Alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study-Rationale and design of the PACMAN-AMI trial</article-title><source>Am Heart J Aug</source><year>2021</year><volume>238</volume><fpage>33</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2021.04.006</pub-id><pub-id pub-id-type="pmid">33951415</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Zanchin C, Koskinas KC, Ueki Y, Losdat S, Haner JD et al (2021) Effects of the PCSK9 antibody Alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study-Rationale and design of the PACMAN-AMI trial. Am Heart J Aug 238:33&#8211;44. 10.1016/j.ahj.2021.04.006<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ahj.2021.04.006</pub-id><pub-id pub-id-type="pmid">33951415</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Byrne</surname><given-names>RA</given-names></name><name name-style="western"><surname>Rossello</surname><given-names>X</given-names></name><name name-style="western"><surname>Coughlan</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Barbato</surname><given-names>E</given-names></name><name name-style="western"><surname>Berry</surname><given-names>C</given-names></name><etal/></person-group><article-title>2023 ESC guidelines for the management of acute coronary syndromes</article-title><source>Eur Heart J Oct</source><year>2023</year><volume>12</volume><issue>38</issue><fpage>3720</fpage><lpage>3826</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehad191</pub-id><pub-id pub-id-type="pmid">37622654</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C et al (2023) 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J Oct 12(38):3720&#8211;3826. 10.1093/eurheartj/ehad191<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehad191</pub-id><pub-id pub-id-type="pmid">37622654</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guagliumi</surname><given-names>G</given-names></name><name name-style="western"><surname>Shimamura</surname><given-names>K</given-names></name><name name-style="western"><surname>Sirbu</surname><given-names>V</given-names></name><name name-style="western"><surname>Garbo</surname><given-names>R</given-names></name><name name-style="western"><surname>Boccuzzi</surname><given-names>G</given-names></name><etal/></person-group><article-title>Temporal course of vascular healing and neoatherosclerosis after implantation of durable- or biodegradable-polymer drug-eluting stents</article-title><source>Eur Heart J Jul</source><year>2018</year><volume>7</volume><issue>26</issue><fpage>2448</fpage><lpage>2456</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehy273</pub-id><pub-id pub-id-type="pmid">29788263</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Guagliumi G, Shimamura K, Sirbu V, Garbo R, Boccuzzi G et al (2018) Temporal course of vascular healing and neoatherosclerosis after implantation of durable- or biodegradable-polymer drug-eluting stents. Eur Heart J Jul 7(26):2448&#8211;2456. 10.1093/eurheartj/ehy273<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehy273</pub-id><pub-id pub-id-type="pmid">29788263</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tearney</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Regar</surname><given-names>E</given-names></name><name name-style="western"><surname>Akasaka</surname><given-names>T</given-names></name><name name-style="western"><surname>Adriaenssens</surname><given-names>T</given-names></name><name name-style="western"><surname>Barlis</surname><given-names>P</given-names></name><etal/></person-group><article-title>Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the international working group for intravascular optical coherence tomography standardization and validation</article-title><source>J Am Coll Cardiol</source><year>2012</year><volume>20</volume><issue>12</issue><fpage>1058</fpage><lpage>1072</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2011.09.079</pub-id><pub-id pub-id-type="pmid">22421299</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Tearney GJ, Regar E, Akasaka T, Adriaenssens T, Barlis P et al (2012) Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the international working group for intravascular optical coherence tomography standardization and validation. J Am Coll Cardiol Mar 20(12):1058&#8211;1072. 10.1016/j.jacc.2011.09.079<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2011.09.079</pub-id><pub-id pub-id-type="pmid">22421299</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoshino</surname><given-names>M</given-names></name><name name-style="western"><surname>Yonetsu</surname><given-names>T</given-names></name><name name-style="western"><surname>Kanaji</surname><given-names>Y</given-names></name><name name-style="western"><surname>Usui</surname><given-names>E</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Impact of baseline plaque characteristic on the development of neoatherosclerosis in the very late phase after stenting</article-title><source>J Cardiol Jul</source><year>2019</year><volume>74</volume><issue>1</issue><fpage>67</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.jjcc.2019.01.002</pub-id><pub-id pub-id-type="pmid">30733110</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Hoshino M, Yonetsu T, Kanaji Y, Usui E, Yamaguchi M et al (2019) Impact of baseline plaque characteristic on the development of neoatherosclerosis in the very late phase after stenting. J Cardiol Jul 74(1):67&#8211;73. 10.1016/j.jjcc.2019.01.002<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jjcc.2019.01.002</pub-id><pub-id pub-id-type="pmid">30733110</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagano</surname><given-names>Y</given-names></name><name name-style="western"><surname>Otake</surname><given-names>H</given-names></name><name name-style="western"><surname>Toba</surname><given-names>T</given-names></name><name name-style="western"><surname>Kuroda</surname><given-names>K</given-names></name><name name-style="western"><surname>Shinkura</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Impaired Cholesterol-Uptake capacity of HDL might promote Target-Lesion revascularization by inducing neoatherosclerosis after stent implantation</article-title><source>J Am Heart Assoc</source><year>2019</year><volume>7</volume><issue>9</issue><fpage>e011975</fpage><pub-id pub-id-type="doi">10.1161/JAHA.119.011975</pub-id><pub-id pub-id-type="pmcid">PMC6512103</pub-id><pub-id pub-id-type="pmid">30995875</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Nagano Y, Otake H, Toba T, Kuroda K, Shinkura Y et al (2019) Impaired Cholesterol-Uptake capacity of HDL might promote Target-Lesion revascularization by inducing neoatherosclerosis after stent implantation. J Am Heart Assoc May 7(9):e011975. 10.1161/JAHA.119.011975<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/JAHA.119.011975</pub-id><pub-id pub-id-type="pmcid">PMC6512103</pub-id><pub-id pub-id-type="pmid">30995875</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Kakizaki R, H&#228;ner J, Taniwaki M, Ohno Y, Yahagi K, THE IMPACT OF ACHIEVING GUIDELINE-ENDORSED LDL CHOLESTEROL LEVELS ON NEOATHEROSCLEROSIS FORMATION IN PATIENTS WITH STEMI (2025) : A SUBSTUDY OF THE RANDOMIZED CONNECT TRIAL. Presented at: American Control Conference 74th Annual Scientific Session; March ; Chicago, IL</mixed-citation></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niccoli</surname><given-names>G</given-names></name><name name-style="western"><surname>Dato</surname><given-names>I</given-names></name><name name-style="western"><surname>Imaeva</surname><given-names>AE</given-names></name><name name-style="western"><surname>Antonazzo Panico</surname><given-names>R</given-names></name><name name-style="western"><surname>Roberto</surname><given-names>M</given-names></name><etal/></person-group><article-title>Association between inflammatory biomarkers and in-stent restenosis tissue features: an optical coherence tomography study</article-title><source>Eur Heart J Cardiovasc Imaging Aug</source><year>2014</year><volume>15</volume><issue>8</issue><fpage>917</fpage><lpage>925</lpage><pub-id pub-id-type="doi">10.1093/ehjci/jeu035</pub-id><pub-id pub-id-type="pmid">24618655</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Niccoli G, Dato I, Imaeva AE, Antonazzo Panico R, Roberto M et al (2014) Association between inflammatory biomarkers and in-stent restenosis tissue features: an optical coherence tomography study. Eur Heart J Cardiovasc Imaging Aug 15(8):917&#8211;925. 10.1093/ehjci/jeu035<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ehjci/jeu035</pub-id><pub-id pub-id-type="pmid">24618655</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>YX</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>HH</given-names></name><name name-style="western"><surname>Li</surname><given-names>JJ</given-names></name></person-group><article-title>Impact of PCSK9 monoclonal antibodies on Circulating hs-CRP levels: a systematic review and meta-analysis of randomised controlled trials</article-title><source>BMJ Open Oct</source><year>2018</year><volume>4</volume><issue>9</issue><fpage>e022348</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2018-022348</pub-id><pub-id pub-id-type="pmcid">PMC6173233</pub-id><pub-id pub-id-type="pmid">30287608</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Cao YX, Li S, Liu HH, Li JJ (2018) Impact of PCSK9 monoclonal antibodies on Circulating hs-CRP levels: a systematic review and meta-analysis of randomised controlled trials. BMJ Open Oct 4(9):e022348. 10.1136/bmjopen-2018-022348<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjopen-2018-022348</pub-id><pub-id pub-id-type="pmcid">PMC6173233</pub-id><pub-id pub-id-type="pmid">30287608</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taniwaki</surname><given-names>M</given-names></name><name name-style="western"><surname>Windecker</surname><given-names>S</given-names></name><name name-style="western"><surname>Zaugg</surname><given-names>S</given-names></name><name name-style="western"><surname>Stefanini</surname><given-names>GG</given-names></name><name name-style="western"><surname>Baumgartner</surname><given-names>S</given-names></name><etal/></person-group><article-title>The association between in-stent neoatherosclerosis and native coronary artery disease progression: a long-term angiographic and optical coherence tomography cohort study</article-title><source>Eur Heart J Aug</source><year>2015</year><volume>21</volume><issue>32</issue><fpage>2167</fpage><lpage>2176</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehv227</pub-id><pub-id pub-id-type="pmid">26040806</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Taniwaki M, Windecker S, Zaugg S, Stefanini GG, Baumgartner S et al (2015) The association between in-stent neoatherosclerosis and native coronary artery disease progression: a long-term angiographic and optical coherence tomography cohort study. Eur Heart J Aug 21(32):2167&#8211;2176. 10.1093/eurheartj/ehv227<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehv227</pub-id><pub-id pub-id-type="pmid">26040806</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakai</surname><given-names>R</given-names></name><name name-style="western"><surname>Sekimoto</surname><given-names>T</given-names></name><name name-style="western"><surname>Koba</surname><given-names>S</given-names></name><name name-style="western"><surname>Mori</surname><given-names>H</given-names></name><name name-style="western"><surname>Matsukawa</surname><given-names>N</given-names></name><etal/></person-group><article-title>Impact of triglyceride-rich lipoproteins on early in-stent neoatherosclerosis formation in patients undergoing Statin treatment</article-title><source>J Clin Lipidol Mar-Apr</source><year>2023</year><volume>17</volume><issue>2</issue><fpage>281</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1016/j.jacl.2023.01.004</pub-id><pub-id pub-id-type="pmid">36828767</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Sakai R, Sekimoto T, Koba S, Mori H, Matsukawa N et al (2023) Impact of triglyceride-rich lipoproteins on early in-stent neoatherosclerosis formation in patients undergoing Statin treatment. J Clin Lipidol Mar-Apr 17(2):281&#8211;290. 10.1016/j.jacl.2023.01.004<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacl.2023.01.004</pub-id><pub-id pub-id-type="pmid">36828767</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">Taniwaki M, Haner JD, Kakizaki R, Ohno Y, Yahagi K et al (2024) Long-term effect of biodegradable vs durable polymer everolimus-eluting stents on neoatherosclerosis in ST-segment elevation myocardial infarction: the CONNECT trial. Eur Heart J Sep 1. 10.1093/eurheartj/ehae589<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehae589</pub-id><pub-id pub-id-type="pmid">39217617</pub-id></mixed-citation></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jang</surname><given-names>JY</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JS</given-names></name><name name-style="western"><surname>Shin</surname><given-names>DH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>BK</given-names></name><name name-style="western"><surname>Ko</surname><given-names>YG</given-names></name><etal/></person-group><article-title>Favorable effect of optimal lipid-lowering therapy on neointimal tissue characteristics after drug-eluting stent implantation: qualitative optical coherence tomographic analysis</article-title><source>Atherosclerosis Oct</source><year>2015</year><volume>242</volume><issue>2</issue><fpage>553</fpage><lpage>559</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2015.08.014</pub-id><pub-id pub-id-type="pmid">26318104</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Jang JY, Kim JS, Shin DH, Kim BK, Ko YG et al (2015) Favorable effect of optimal lipid-lowering therapy on neointimal tissue characteristics after drug-eluting stent implantation: qualitative optical coherence tomographic analysis. Atherosclerosis Oct 242(2):553&#8211;559. 10.1016/j.atherosclerosis.2015.08.014<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.atherosclerosis.2015.08.014</pub-id><pub-id pub-id-type="pmid">26318104</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakamura</surname><given-names>D</given-names></name><name name-style="western"><surname>Dohi</surname><given-names>T</given-names></name><name name-style="western"><surname>Ishihara</surname><given-names>T</given-names></name><name name-style="western"><surname>Kikuchi</surname><given-names>A</given-names></name><name name-style="western"><surname>Mori</surname><given-names>N</given-names></name><etal/></person-group><article-title>Predictors and outcomes of neoatherosclerosis in patients with in-stent restenosis</article-title><source>EuroIntervention Aug</source><year>2021</year><volume>27</volume><issue>6</issue><fpage>489</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.4244/EIJ-D-20-00539</pub-id><pub-id pub-id-type="pmcid">PMC9725017</pub-id><pub-id pub-id-type="pmid">32985411</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Nakamura D, Dohi T, Ishihara T, Kikuchi A, Mori N et al (2021) Predictors and outcomes of neoatherosclerosis in patients with in-stent restenosis. EuroIntervention Aug 27(6):489&#8211;496. 10.4244/EIJ-D-20-00539<pub-id pub-id-type="doi" assigning-authority="pmc">10.4244/EIJ-D-20-00539</pub-id><pub-id pub-id-type="pmcid">PMC9725017</pub-id><pub-id pub-id-type="pmid">32985411</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>X</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>M</given-names></name><name name-style="western"><surname>Feng</surname><given-names>H</given-names></name><etal/></person-group><article-title>Lipoprotein (a) is related to In-Stent neoatherosclerosis incidence rate and plaque vulnerability: optical coherence tomography study</article-title><source>Int J Cardiovasc Imaging Feb</source><year>2023</year><volume>39</volume><issue>2</issue><fpage>275</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1007/s10554-022-02736-3</pub-id><pub-id pub-id-type="pmcid">PMC9870965</pub-id><pub-id pub-id-type="pmid">36315364</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Yuan X, Han Y, Hu X, Jiang M, Feng H et al (2023) Lipoprotein (a) is related to In-Stent neoatherosclerosis incidence rate and plaque vulnerability: optical coherence tomography study. Int J Cardiovasc Imaging Feb 39(2):275&#8211;284. 10.1007/s10554-022-02736-3<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10554-022-02736-3</pub-id><pub-id pub-id-type="pmcid">PMC9870965</pub-id><pub-id pub-id-type="pmid">36315364</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Furtado</surname><given-names>RHM</given-names></name><name name-style="western"><surname>Fagundes</surname><given-names>AA</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Oyama</surname><given-names>K</given-names></name><name name-style="western"><surname>Zelniker</surname><given-names>TA</given-names></name><name name-style="western"><surname>Tang</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effect of Evolocumab in patients with prior percutaneous coronary intervention</article-title><source>Circ Cardiovasc Interv Mar</source><year>2022</year><volume>15</volume><issue>3</issue><fpage>e011382</fpage><pub-id pub-id-type="doi">10.1161/CIRCINTERVENTIONS.121.011382</pub-id><pub-id pub-id-type="pmid">35209731</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Furtado RHM, Fagundes AA Jr., Oyama K, Zelniker TA, Tang M et al (2022) Effect of Evolocumab in patients with prior percutaneous coronary intervention. Circ Cardiovasc Interv Mar 15(3):e011382. 10.1161/CIRCINTERVENTIONS.121.011382<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCINTERVENTIONS.121.011382</pub-id><pub-id pub-id-type="pmid">35209731</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yonetsu</surname><given-names>T</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JS</given-names></name><name name-style="western"><surname>Kato</surname><given-names>K</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Xing</surname><given-names>L</given-names></name><etal/></person-group><article-title>Comparison of incidence and time course of neoatherosclerosis between bare metal stents and drug-eluting stents using optical coherence tomography</article-title><source>Am J Cardiol</source><year>2012</year><volume>1</volume><issue>7</issue><fpage>933</fpage><lpage>939</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2012.05.027</pub-id><pub-id pub-id-type="pmid">22727183</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Yonetsu T, Kim JS, Kato K, Kim SJ, Xing L et al (2012) Comparison of incidence and time course of neoatherosclerosis between bare metal stents and drug-eluting stents using optical coherence tomography. Am J Cardiol Oct 1(7):933&#8211;939. 10.1016/j.amjcard.2012.05.027<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amjcard.2012.05.027</pub-id><pub-id pub-id-type="pmid">22727183</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>L</given-names></name><name name-style="western"><surname>Mintz</surname><given-names>GS</given-names></name><name name-style="western"><surname>Yin</surname><given-names>D</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>MH</given-names></name><name name-style="western"><surname>Chin</surname><given-names>CY</given-names></name><etal/></person-group><article-title>Neoatherosclerosis assessed with optical coherence tomography in restenotic bare metal and first- and second-generation drug-eluting stents</article-title><source>Int J Cardiovasc Imaging Aug</source><year>2017</year><volume>33</volume><issue>8</issue><fpage>1115</fpage><lpage>1124</lpage><pub-id pub-id-type="doi">10.1007/s10554-017-1106-2</pub-id><pub-id pub-id-type="pmid">28281026</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Song L, Mintz GS, Yin D, Yamamoto MH, Chin CY et al (2017) Neoatherosclerosis assessed with optical coherence tomography in restenotic bare metal and first- and second-generation drug-eluting stents. Int J Cardiovasc Imaging Aug 33(8):1115&#8211;1124. 10.1007/s10554-017-1106-2<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10554-017-1106-2</pub-id><pub-id pub-id-type="pmid">28281026</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>SY</given-names></name><name name-style="western"><surname>Hur</surname><given-names>SH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SG</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SW</given-names></name><name name-style="western"><surname>Shin</surname><given-names>DH</given-names></name><etal/></person-group><article-title>Optical coherence tomographic observation of in-stent neoatherosclerosis in lesions with more than 50% neointimal area stenosis after second-generation drug-eluting stent implantation</article-title><source>Circ Cardiovasc Interv Feb</source><year>2015</year><volume>8</volume><issue>2</issue><fpage>e001878</fpage><pub-id pub-id-type="doi">10.1161/CIRCINTERVENTIONS.114.001878</pub-id><pub-id pub-id-type="pmid">25613674</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Lee SY, Hur SH, Lee SG, Kim SW, Shin DH et al (2015) Optical coherence tomographic observation of in-stent neoatherosclerosis in lesions with more than 50% neointimal area stenosis after second-generation drug-eluting stent implantation. Circ Cardiovasc Interv Feb 8(2):e001878. 10.1161/CIRCINTERVENTIONS.114.001878<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCINTERVENTIONS.114.001878</pub-id><pub-id pub-id-type="pmid">25613674</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jinnouchi</surname><given-names>H</given-names></name><name name-style="western"><surname>Otsuka</surname><given-names>F</given-names></name><name name-style="western"><surname>Sato</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bhoite</surname><given-names>RR</given-names></name><name name-style="western"><surname>Sakamoto</surname><given-names>A</given-names></name><etal/></person-group><article-title>Healthy strut coverage after coronary stent implantation: an ex vivo human autopsy study</article-title><source>Circ Cardiovasc Interv May</source><year>2020</year><volume>13</volume><issue>5</issue><fpage>e008869</fpage><pub-id pub-id-type="doi">10.1161/CIRCINTERVENTIONS.119.008869</pub-id><pub-id pub-id-type="pmid">32338525</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Jinnouchi H, Otsuka F, Sato Y, Bhoite RR, Sakamoto A et al (2020) Healthy strut coverage after coronary stent implantation: an ex vivo human autopsy study. Circ Cardiovasc Interv May 13(5):e008869. 10.1161/CIRCINTERVENTIONS.119.008869<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCINTERVENTIONS.119.008869</pub-id><pub-id pub-id-type="pmid">32338525</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>